SCHEMBL477137

SCHEMBL477137

Cc1nc2ccc(N3CC4CN(C(C)C)CC4C3)nn2c1-c1ccnc(N)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 4/20 0.44
KDR P35968 1/20 0.33
TGFBR1 P36897 1/20 0.33
CLK2 P49760 1/20 0.32
DYRK1A Q13627 1/20 0.32
HASPIN Q8TF76 1/20 0.32
RIPK3 Q9Y572 6/20 0.32
TLR9 Q9NR96 2/20 0.32
TLR8 Q9NR97 2/20 0.32
TLR7 Q9NYK1 2/20 0.32
AAK1 Q2M2I8 2/20 0.32
HRH4 Q9H3N8 1/20 0.31
IRAK4 Q9NWZ3 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4D Q08499 1/20 0.31
KCNH2 Q12809 1/20 0.31
MAPK14 Q16539 1/20 0.31
PIK3CD O00329 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL477000 0.86 CSNK1E (0.51) CSNK1EKDRTGFBR1CLK2DYRK1A
SCHEMBL477118 0.86 CSNK1E (0.60) CSNK1ECLK2DYRK1AHASPINRIPK3
SCHEMBL477052 0.83 CSNK1E (0.49) CSNK1EKDRTGFBR1CLK2DYRK1A
SCHEMBL477051 0.83 CSNK1E (0.49) CSNK1EKDRTGFBR1CLK2DYRK1A
SCHEMBL477063 0.82 HRH3 (0.52) CSNK1ERIPK3
SCHEMBL3104250 0.79 CSNK1E (0.51) CSNK1ERIPK3MAPK14
SCHEMBL477117 0.78 CSNK1E (0.56) CSNK1E
SCHEMBL477096 0.78 CSNK1E (0.56) CSNK1E
SCHEMBL477095 0.78 CSNK1E (0.56) CSNK1E
SCHEMBL477076 0.77 CSNK1E (0.55) CSNK1ERIPK3TLR9TLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2331546-B1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2012-02-01 EP claimed
US-20110312934-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2011-12-22 US claimed
EP-2331546-B1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2012-02-01 EP disclosed
US-20110312934-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312934-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF NR3C1, CNKSR1, NR3C2 CSNK1E 2760/4885KDR 261/4885TGFBR1 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.